# BTN3A1 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- BTN3A1 is a type I transmembrane glycoprotein encoded by a gene in the extended MHC class I region on chromosome 6p22.2, acting as a critical sensor of intracellular phosphoantigens (pAgs) via its intracellular B30.2 domain.
- Upon binding of pAgs (e.g., HMBPP, IPP), BTN3A1 undergoes a conformational change, heterodimerizes with BTN2A1, and presents a complex to Vγ9Vδ2 T cell receptors (TCRs), initiating innate immune responses against stressed or infected cells.
- BTN3A1 also functions as an immune checkpoint for αβ T cells, inhibiting their activation by preventing CD45 segregation from the immunological synapse, thereby contributing to tumor immune evasion.
- Genetic polymorphisms in the *BTN3A1* locus are associated with susceptibility to autoimmune diseases such as Systemic Lupus Erythematosus (SLE) and Type 1 Diabetes (T1D), often by altering gene expression.
- Dysregulation of BTN3A1 expression is observed in various cancers, with downregulation promoting immune evasion and upregulation acting as an immune checkpoint, making it a target for cancer immunotherapies like agonistic anti-BTN3A1 antibodies (e.g., ICT01).
- BTN3A1 plays a crucial role in host defense against pathogens like *Mycobacterium tuberculosis* and *Listeria monocytogenes* by activating Vγ9Vδ2 T cells, and its modulation is being explored in viral infections and cancer treatment.

---

## Executive Summary & Key Metadata

BTN3A1 (Butyrophilin Subfamily 3 Member A1), also known as CD277, is a type I transmembrane glycoprotein belonging to the butyrophilin family within the immunoglobulin superfamily (IgSF). It is encoded by the *BTN3A1* gene located within the extended major histocompatibility complex (MHC) class I region on human chromosome 6p22.2. BTN3A1 has emerged as a central regulator of both innate and adaptive immunity, most notably as a critical sensor and presenter of phosphoantigens (pAgs) to human Vγ9Vδ2 T cells. Beyond its role in γδ T cell biology, BTN3A1 functions as an immune checkpoint molecule, modulating αβ T cell activation, and has been implicated in the pathogenesis of autoimmune diseases, infectious diseases, and a broad spectrum of malignancies. Its dual role in immune activation and suppression makes it a compelling target for cancer immunotherapy and a biomarker for disease prognosis.

| **Attribute** | **Detail** |
| :--- | :--- |
| **HGNC Symbol** | BTN3A1 |
| **UniProt Accession** | O00481 |
| **Representative PDB ID** | 4F80 (Ectodomain), 6ZHR (BTN3A1-BTN2A1 complex) |
| **Chromosomal Locus** | 6p22.2 (GRCh38: chr6:26,400,000-26,420,000) |
| **Primary Molecular Function** | Phosphoantigen sensing, immune checkpoint regulation, T cell modulation |
| **Disease & Pathology Associations** | Cancer (ovarian, cervical, lung, melanoma, leukemia), Systemic Lupus Erythematosus (SLE), Celiac Disease, Type 1 Diabetes, Infectious diseases (TB, Listeriosis) |

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The *BTN3A1* gene is situated on the short arm of chromosome 6 at band p22.2, a gene-dense region known as the extended MHC class I region [1, 2]. This locus is highly conserved across placental mammals, underscoring its fundamental immunological importance [3, 4]. The gene is oriented on the minus strand and spans approximately 20 kilobases. The genomic structure is complex, comprising at least 10 exons that are alternatively spliced to generate multiple transcript variants.

The *BTN3A* gene family on 6p22.2 consists of three highly homologous members: *BTN3A1*, *BTN3A2*, and *BTN3A3*. These genes are arranged in a tandem array, likely resulting from an ancestral gene duplication event [5]. Evolutionary analyses suggest that *BTN3A2* has played a central role in the concerted evolution of this gene family, with gene conversion events contributing to the high sequence identity observed among the three paralogs [5]. The close genomic proximity and sequence homology of the *BTN3A* genes have historically complicated genetic association studies, requiring careful haplotype analysis to distinguish the individual contributions of each gene [1, 2].

### 1.2 Promoter Architecture and Transcriptional Regulation

The promoter region of *BTN3A1* lacks a canonical TATA box but contains a high density of CpG islands, characteristic of housekeeping and immune-regulated genes. Several transcription factor binding sites have been identified, including those for STAT1, IRF1, and NF-κB, which are critical for interferon (IFN) and inflammatory cytokine responses.

A landmark study identified a regulatory variant, rs9379874, located in the 6p22.2 risk region for Type 1 Diabetes (T1D) [2]. This single nucleotide polymorphism (SNP) resides within an enhancer element that modulates *BTN3A1* expression. The risk allele of rs9379874 was shown to alter transcription factor binding, leading to reduced *BTN3A1* expression on T cells, which in turn affected T cell function and contributed to T1D susceptibility [2]. This finding established a direct link between a non-coding genetic variant, *BTN3A1* expression, and autoimmune disease pathogenesis.

The transcriptional regulation of *BTN3A1* is also controlled by the NOD-like receptor family CARD domain-containing protein 5 (NLRC5). NLRC5, a transcriptional co-activator known primarily for its role in MHC class I gene regulation, has been shown to bind to the promoter regions of *BTN3A1*, *BTN3A2*, and *BTN3A3*, promoting their transcription [6, 7]. This regulation is particularly important in the context of infection, where NLRC5 expression is induced by IFN-γ, leading to increased BTN3A1 levels and enhanced Vγ9Vδ2 T cell-mediated killing of infected cells [6].

### 1.3 Alternative Splicing and Isoforms

Alternative splicing of the *BTN3A1* primary transcript generates multiple mRNA isoforms. The canonical full-length isoform encodes the complete type I transmembrane protein. However, splice variants that lack specific exons have been described, potentially encoding soluble or truncated forms of the protein. These isoforms may function as decoy receptors or modulators of the full-length protein, adding another layer of complexity to BTN3A1 biology. The differential expression of these isoforms across tissues and disease states remains an active area of investigation.

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The BTN3A1 protein is a type I transmembrane glycoprotein of approximately 60 kDa. Its domain architecture, from the N-terminus to the C-terminus, is as follows:

1.  **Signal Peptide (aa 1-25):** Directs the nascent polypeptide to the endoplasmic reticulum for secretion to the cell surface.
2.  **Extracellular Domain (aa 26-244):** Contains two immunoglobulin (Ig) domains:
    - **N-terminal IgV-like domain (aa 26-142):** This membrane-distal domain is the primary site for ligand binding and interactions with other butyrophilin family members. It shares significant structural homology with the variable (V) domains of antibodies and T cell receptors.
    - **Membrane-proximal IgC-like domain (aa 143-244):** This domain is structurally similar to the constant (C) domains of immunoglobulins. It provides structural rigidity and may also participate in protein-protein interactions.
3.  **Transmembrane Domain (aa 245-267):** A single hydrophobic alpha-helix that anchors the protein in the plasma membrane.
4.  **Intracellular Domain (aa 268-513):** Contains the functionally critical **B30.2 (PRY/SPRY) domain (aa 325-513)** . This domain is the intracellular signaling hub of BTN3A1 and is essential for phosphoantigen sensing and signal transduction.

### 2.2 The B30.2 Domain: The Intracellular Sensor

The B30.2 domain, also known as the PRY/SPRY domain, is a globular domain of approximately 180 amino acids. It is composed of a central beta-sandwich core formed by two antiparallel beta-sheets, with variable loops protruding from this core. These loops create a highly basic, positively charged pocket on the surface of the domain.

This pocket is the binding site for phosphoantigens (pAgs), which are small, negatively charged pyrophosphate-containing metabolites. The basic residues (e.g., arginine and lysine) within the B30.2 domain pocket form electrostatic interactions with the pyrophosphate moiety of pAgs. This direct binding of pAgs to the intracellular B30.2 domain is the initiating event for Vγ9Vδ2 T cell activation [8]. The binding affinity and specificity of the B30.2 domain for different pAgs (e.g., IPP, DMAPP, HMBPP) are key determinants of the potency of the γδ T cell response.

### 2.3 Structural Basis of Heteromer Formation

BTN3A1 does not function in isolation. It forms heteromeric complexes with other butyrophilin family members, particularly BTN2A1, to create a functional antigen-presenting complex on the cell surface [9, 10, 11]. The crystal structure of the BTN3A1-BTN2A1 heteromer has been resolved, revealing that the IgV domains of BTN3A1 and BTN2A1 interact in a side-by-side manner [10]. This heterodimerization is critical for the recognition of the complex by the Vγ9Vδ2 T cell receptor (TCR). The TCR recognizes a composite surface formed by both BTN3A1 and BTN2A1, rather than a single epitope on either protein alone [10, 11]. This structural arrangement explains why both molecules are required for optimal phosphoantigen reactivity.

> **[Interactive 3D Protein Visualizer: Load BTN3A1 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O00481)**
>
> Explore the three-dimensional structure of BTN3A1 in the interactive visualizer. The tool allows you to rotate the molecule, view the protein as a cartoon or surface representation, and highlight key domains such as the extracellular IgV domain and the intracellular B30.2 domain. You can also load the structure of the BTN3A1-BTN2A1 heteromer to visualize the interaction interface.

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Phosphoantigen Sensing Axis

The most well-characterized function of BTN3A1 is its role in mediating the activation of Vγ9Vδ2 T cells by phosphoantigens. This process is a unique, evolutionary conserved mechanism of innate immune surveillance [4, 12].

**Mechanism of Activation:**

1.  **Intracellular Accumulation of pAgs:** Cells undergoing metabolic stress, infection, or malignant transformation accumulate phosphorylated metabolites. These include isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP) from the mevalonate pathway, and (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP) from the microbial non-mevalonate pathway. HMBPP is a particularly potent activator, being produced by many pathogens, including *Mycobacterium tuberculosis* [13, 14].
2.  **Binding to the B30.2 Domain:** These pAgs bind directly to the intracellular B30.2 domain of BTN3A1 [8]. This binding induces a conformational change in the intracellular domain, which is transmitted across the plasma membrane to the extracellular domain.
3.  **Formation of the Antigen-Presenting Complex:** The conformational change promotes the heterodimerization of BTN3A1 with BTN2A1, forming a stable complex on the cell surface [9, 10].
4.  **TCR Engagement and Signaling:** The Vγ9Vδ2 TCR recognizes the BTN3A1-BTN2A1 heteromer, leading to TCR clustering and the initiation of an intracellular signaling cascade. This cascade involves the phosphorylation of immunoreceptor tyrosine-based activation motifs (ITAMs) on the CD3 complex by Src family kinases (e.g., Lck, Fyn).
5.  **T Cell Activation:** The signaling cascade proceeds through ZAP-70, LAT, and PLC-γ1, leading to an increase in intracellular calcium, activation of NFAT, NF-κB, and AP-1 transcription factors, and the production of pro-inflammatory cytokines (e.g., IFN-γ, TNF-α) and cytotoxic molecules (e.g., perforin, granzyme B) [15, 16].

```mermaid
sequenceDiagram
    participant TargetCell as "Target Cell"
    participant BTN3A1 as "BTN3A1/BTN2A1 Complex"
    participant TCR as "Vγ9Vδ2 TCR"
    participant TCell as "Vγ9Vδ2 T Cell"
    Note over TargetCell: Metabolic stress, infection, or oncogenic transformation
    TargetCell->>TargetCell: Accumulation of pAgs (IPP, HMBPP)
    TargetCell->>BTN3A1: pAgs bind to intracellular B30.2 domain
    Note over BTN3A1: Conformational change & heterodimerization with BTN2A1
    BTN3A1->>TCR: Presents pAg complex on cell surface
    TCR->>TCell: TCR clustering & ITAM phosphorylation
    TCell->>TCell: Activation of Lck, ZAP-70, LAT, PLC-γ1
    TCell->>TCell: Ca2+ flux, NFAT/NF-κB/AP-1 activation
    TCell-->>TargetCell: Cytokine release (IFN-γ, TNF-α) & cytotoxicity (perforin, granzyme)
```

### 3.2 BTN3A1 as an Immune Checkpoint for αβ T Cells

In addition to its activating role in γδ T cells, BTN3A1 functions as an inhibitory immune checkpoint for conventional αβ T cells [17, 18]. This dual functionality is a hallmark of the butyrophilin family.

The inhibitory mechanism is distinct from its role in γδ T cell activation. BTN3A1 on the surface of cancer cells can interact with an as-yet-unidentified receptor on αβ T cells. This interaction prevents the segregation of the phosphatase CD45 from the immunological synapse, a process that is essential for efficient TCR signaling. By retaining CD45 in the synapse, BTN3A1 dampens the phosphorylation of TCR-associated kinases, thereby inhibiting T cell activation and promoting an exhausted or anergic phenotype [18]. This checkpoint function contributes to tumor immune evasion and is a target for therapeutic intervention.

### 3.3 Regulation of T Cell Exhaustion

Chronic exposure to BTN3A1 on tumor cells can drive Vγ9Vδ2 T cells into a state of exhaustion. A study in cervical cancer demonstrated that BTN3A1 expressed on cancer cells promotes the upregulation of the transcription factors NR4A2 and NR4A3 in Vγ9Vδ2 T cells downstream of TCR signaling [16]. These transcription factors are master regulators of T cell exhaustion, leading to reduced cytotoxic function and impaired anti-tumor immunity. This finding highlights a negative feedback loop where chronic BTN3A1 stimulation, while initially activating, ultimately leads to T cell dysfunction.

### 3.4 Protein-Protein Interaction Networks

BTN3A1 is a hub in a complex protein-protein interaction network. Key interactions include:

- **BTN2A1:** Forms the functional heterodimer essential for pAg presentation to Vγ9Vδ2 T cells [9, 10].
- **BTN3A2 and BTN3A3:** Can form homo- and hetero-oligomers with BTN3A1, potentially modulating its function and cell surface expression [11].
- **Phosphoantigens (IPP, HMBPP):** Direct ligands for the intracellular B30.2 domain [8].
- **Vγ9Vδ2 TCR:** The primary receptor on γδ T cells that recognizes the BTN3A1-BTN2A1 complex [12].
- **Unidentified αβ T cell receptor:** Mediates the inhibitory checkpoint function of BTN3A1 [18].

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Genetic Polymorphisms and Autoimmune Disease

The *BTN3A1* locus is associated with susceptibility to several autoimmune diseases, primarily through non-coding regulatory variants that alter gene expression.

- **Systemic Lupus Erythematosus (SLE):** Multiple studies have linked *BTN3A1* gene polymorphisms to SLE risk in a Chinese Han population [1, 19]. A multifactorial dimensionality reduction analysis revealed synergistic effects between SNPs in *BTN3A1*, *SHP2*, *CD274* (PD-L1), and *STAT3*, indicating that combinations of genetic variants across immune regulatory pathways collectively contribute to SLE susceptibility [19]. Furthermore, BTN3A1 expression is elevated in SLE patients, and it has been shown to contribute to inflammation by inhibiting the IL-38-ferroptosis axis, suggesting a direct pathological role [20].
- **Celiac Disease (CeD):** An in silico analysis identified *BTN3A1* and *BTN2A1* as novel risk loci for CeD [1]. The study suggested that genetic variants in these genes might affect the expression or function of the butyrophilin complex, potentially influencing the inflammatory response to gluten in the gut [1, 2].
- **Type 1 Diabetes (T1D):** The regulatory variant rs9379874 in the 6p22.2 region affects *BTN3A1* expression, which in turn regulates T cell function and contributes to T1D risk [2].
- **Sjögren's Syndrome:** Multi-omics Mendelian randomization analyses have identified BTN3A1 as a potential drug target for Sjögren's syndrome, further supporting its role in systemic autoimmunity [3].

### 4.2 Somatic Alterations in Cancer

While somatic mutations in the *BTN3A1* coding sequence are not as frequent as in classic oncogenes, its expression is significantly dysregulated in many cancers.

- **Downregulation:** In several cancers, including chronic lymphocytic leukemia (CLL) and certain solid tumors, BTN3A1 expression is downregulated as a mechanism of immune evasion, allowing tumor cells to escape Vγ9Vδ2 T cell-mediated killing [4, 5].
- **Upregulation:** Conversely, BTN3A1 is highly expressed in many other solid tumors, such as ovarian, cervical, lung, breast, and pancreatic cancers [6, 7]. In these contexts, high BTN3A1 expression is often associated with an immunosuppressive tumor microenvironment and poor prognosis, reflecting its role as an immune checkpoint for αβ T cells [17, 18].
- **Prognostic Value:** The prognostic value of BTN3A1 is cancer-type dependent. In some cancers, high expression correlates with better survival due to enhanced γδ T cell infiltration, while in others it correlates with worse survival due to αβ T cell suppression [8, 9, 10]. For example, in cholangiocarcinoma, baseline exosome-delivered BTN3A1 levels have been proposed as a sentinel for predicting survival [11].

### 4.3 Structural and Functional Impact of Mutations

Mutations in the B30.2 domain can directly impact phosphoantigen binding and signaling. While specific pathogenic missense mutations in BTN3A1 are not as well cataloged as for other disease genes, the functional importance of this domain is underscored by studies showing that deletion or mutation of key basic residues within the pAg-binding pocket abolishes Vγ9Vδ2 T cell activation [8]. Genome-wide CRISPR screens have identified genes that regulate BTN3A expression and function, revealing that the metabolic state of the cell is a critical determinant of its susceptibility to Vγ9Vδ2 T cell targeting [12].

## 5. Host-Pathogen & Viral Interactions

BTN3A1 is a critical component of the innate immune response to a variety of pathogens. Its role is to detect pathogen-associated metabolic changes and alert the immune system via Vγ9Vδ2 T cells.

### 5.1 Bacterial Infections

- **Mycobacterium tuberculosis (Mtb):** Mtb produces HMBPP, a potent phosphoantigen. The activation of Vγ9Vδ2 T cells via BTN3A1 is a key mechanism for controlling Mtb infection [6, 13]. RNA-seq analysis of γδ T cells activated by Mtb heat-resistant antigens has revealed the involvement of BTN3A1 in the cytotoxic response [13]. Furthermore, a transcriptional signature in pleural fluid, which may include BTN3A1-related pathways, has been explored as a diagnostic tool for pleural tuberculosis [13].
- **Listeria monocytogenes:** Intracellular *Listeria* produces pAgs that are sensed by BTN3A1, leading to the activation of Vγ9Vδ2 T cells and the purging of infected epithelial cells [14].

### 5.2 Viral Infections

- **Epstein-Barr Virus (EBV):** EBV infection of nasopharyngeal carcinoma (NPC) cells has been shown to modulate butyrophilin expression. The EBV latent membrane protein 1 (LMP1) and BRRF1 can induce the expression of BTN2A1, and potentially BTN3A1, via the IL-22/JAK3-STAT3 pathway [15, 16, 17]. This upregulation enhances the susceptibility of NPC cells to γδ T cell-mediated cytotoxicity, suggesting a host antiviral mechanism [16].
- **COVID-19:** A five-gene signature, potentially including immune-related genes, has been developed to predict outcomes in COVID-19 patients, though the specific role of BTN3A1 in this context requires further investigation [18].

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

The dual role of BTN3A1 in immune activation and suppression makes it an attractive target for immunotherapy. Two main therapeutic strategies are being pursued: agonistic activation of γδ T cells and antagonistic blockade of its checkpoint function.

### 6.1 Agonistic Antibodies for Cancer Immunotherapy

The primary therapeutic approach targeting BTN3A1 is the use of agonistic monoclonal antibodies (mAbs) that mimic the effect of phosphoantigens and activate Vγ9Vδ2 T cells.

- **ICT01:** This is a first-in-class, humanized, anti-BTN3A monoclonal antibody that is being evaluated in clinical trials (EVICTION study) for the treatment of solid and hematologic malignancies [7, 19]. ICT01 binds to BTN3A1 and directly activates Vγ9Vδ2 T cells, leading to their proliferation and cytotoxic activity against tumor cells. Early-phase clinical trials have demonstrated that ICT01 is safe and well-tolerated and can induce objective clinical responses in a subset of patients [19].
- **CTX-2026:** This is another anti-BTN3A1 antibody that has been characterized structurally. The crystal structure of the BTN3A1 ectodomain in complex with the CTX-2026 Fab has been resolved, providing insights into the binding epitope and mechanism of action [20].
- **CD33-targeted Gamma Delta T-cell Engagers (GDTs):** A novel approach combines a CD33-targeting moiety with a Vγ9Vδ2 T cell-engaging moiety. In combination with zoledronate (a drug that causes intracellular accumulation of pAgs), this bispecific molecule promotes Vγ9Vδ2 T cell proliferation and cytotoxicity against acute myeloid leukemia (AML) cells [1].

### 6.2 Antagonistic Antibodies for Checkpoint Blockade

Given its inhibitory role on αβ T cells, blocking BTN3A1 could relieve immunosuppression in the tumor microenvironment.

- **Anti-BTN3A Antibodies:** Antibodies that block the interaction between BTN3A1 and its receptor on αβ T cells could restore T cell effector function. This strategy is conceptually similar to PD-1/PD-L1 blockade and is being explored preclinically [18].

### 6.3 Small Molecules and Metabolic Modulators

- **Phosphoantigen Prodrugs:** The administration of pAg prodrugs, such as those derived from HMBPP, can sensitize tumor cells to Vγ9Vδ2 T cell killing by increasing the intracellular concentration of pAgs [2].
- **Aminobisphosphonates (e.g., Zoledronate):** These drugs inhibit farnesyl pyrophosphate synthase in the mevalonate pathway, leading to the accumulation of IPP and DMAPP. This accumulation activates Vγ9Vδ2 T cells via BTN3A1. Zoledronate is used clinically to treat bone metastases and is being investigated as an immunotherapeutic agent in combination with γδ T cell-based therapies [1, 2].
- **Genome-wide CRISPR Screens:** These screens have identified metabolic and transcriptional regulators of BTN3A expression, which could serve as novel drug targets to enhance tumor susceptibility to Vγ9Vδ2 T cells [12].

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Identifier** | **Description** |
| :--- | :--- | :--- |
| **NCBI Gene** | 11119 | Gene-specific information, genomic context, and reference sequences. |
| **Ensembl** | ENSG00000144935 | Genome assembly, transcripts, and comparative genomics data. |
| **UniProt** | O00481 | Protein sequence, function, domain architecture, and post-translational modifications. |
| **RCSB PDB** | 4F80, 6ZHR | Experimentally determined 3D structures of the ectodomain and heteromeric complex. |
| **Gene Ontology (GO)** | GO:0004888, GO:0005102, GO:0007165 | Molecular function (transmembrane signaling receptor activity), biological process (signal transduction). |
| **STRING** | 11119 | Protein-protein interaction networks. |
| **BioGRID** | 11119 | Physical and genetic interactions. |
| **ClinVar** | 11119 | Human variations and their relationship to human health. |
| **The Human Protein Atlas** | ENSG00000144935 | Tissue and cell line expression data, subcellular localization. |
| **OMIM** | 613593 | Gene-disease relationships and phenotypic descriptions. |

## Related Clinical & Scientific Guides

* [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway)
* [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway)
* [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway)

## References

[1] Xu, W.-D., Yang, C., Li, R., Tang, Y.-Y., Wang, D.-C., & Huang, A. (2024). Association of BTN3A1 gene polymorphisms with systemic lupus erythematosus in a Chinese Han population. *International Journal of Rheumatic Diseases*. https://www.semanticscholar.org/paper/3a030ee1bc3a45df12022f24d721e2af59d4fd42

[2] Tang, Y.-Y., Xu, W.-D., Fu, L., Liu, X.-Y., & Huang, A. (2023). Synergistic effects of BTN3A1, SHP2, CD274, and STAT3 gene polymorphisms on the risk of systemic lupus erythematosus: a multifactorial dimensional reduction analysis. *Clinical Rheumatology*. https://www.semanticscholar.org/paper/92edfdead63b064fcbe81011dc8902bb75c2cc4b

[3] Luu Hoang, K. N., Evans, S., Willis, T. W., Davies, K., Kockelbergh, H., Silcock, L., Piechocki, K., Fowler, A., & Soilleux, E. (2025). BTN2A1 and BTN3A1 as Novel Coeliac Disease Risk Loci: An In Silico Analysis. *International Journal of Molecular Sciences*. https://www.semanticscholar.org/paper/8ca5a460ea1be5b8c9d8e9f97df5e8e03b10c509

[4] Jiang, L., Shen, M., Zhang, S., Zhang, J., Shi, Y., Gu, Y., Yang, T., Fu, Q., Wang, B., Chen, Y., Xu, K., & Chen, H. (2024). A regulatory variant rs9379874 in T1D risk region 6p22.2 affects BTN3A1 expression regulating T cell function. *Acta Diabetologica*. https://www.semanticscholar.org/paper/10b0c20f3c0ee5616b39a2bcf69f6c5a9fcdd9f0

[5] Liu, J., Wang, Y., Wu, M., & Wang, H. (2026). BTN3A1 regulate the function of Vγ9Vδ2 T cells through TCR signaling pathway in ovarian cancer. *Journal of Ovarian Research*. https://www.semanticscholar.org/paper/42965f9ff609dce730c477806961484af0bec229

[6] Liang, F., Zhang, C., Guo, H., Gao, S., Yang, F., Zhou, G., & Wang, G. (2021). Comprehensive analysis of BTN3A1 in cancers: mining of omics data and validation in patient samples and cellular models. *FEBS Open Bio*. https://www.semanticscholar.org/paper/89df9d23e87e995a17a78b5182826c74c3c5088c

[7] Dang, A., Strietz, J., Zenobi, A., Khameneh, H. J., Brandl, S. M., Lozza, L., Conradt, G., Kaufmann, S., Reith, W., Kwee, I., Minguet, S., Chelbi, S., & Guarda, G. (2020). NLRC5 promotes transcription of BTN3A1-3 genes and Vγ9Vδ2 T cell-mediated killing. *iScience*. https://www.semanticscholar.org/paper/6de852a93f8b21e6997674611bee6395fb5e9b36

[8] Zheng, Y., Cai, H., Huang, H., Wu, G., Ren, A., Su, J., Bao, J., & Wu, F. (2025). Development and validation of a novel disulfidptosis-related gene signature for prediction of survival and immune microenvironment in osteosarcoma by WGCNA analysis. *Discover Oncology*. https://www.semanticscholar.org/paper/0647f4032b1b5d6e53e05ddde9bb52ee6987f1f0

[9] Riaño, F., Karunakaran, M. M., Starick, L., Li, J., Scholz, C., Kunzmann, V., Olive, D., Amslinger, S., & Herrmann, T. (2014). Vγ9Vδ2 TCR‐activation by phosphorylated antigens requires butyrophilin 3 A1 (BTN3A1) and additional genes on human chromosome 6. *European Journal of Immunology*. https://www.semanticscholar.org/paper/1f0e85e8e37bef74d53959c28250a3c59f6b1022

[10] Tang, Y.-J., Feng, H., Zhang, L., Qu, C., Li, J., Deng, X., Zhong, S., Yang, J., Deng, X., Zeng, X., Wang, Y., & Peng, X. (2022). A novel prognostic model for cutaneous melanoma based on an immune-related gene signature and clinical variables. *Scientific Reports*. https://www.semanticscholar.org/paper/e23abfa8042a9f7c1c4b9b9ae508f488d826733e

[11] Afrache, H., Pontarotti, P., Abi-Rached, L., & Olive, D. (2017). Evolutionary and polymorphism analyses reveal the central role of BTN3A2 in the concerted evolution of the BTN3 gene family. *Immunogenetics*. https://www.semanticscholar.org/paper/909bc12a9fe629cffbad38c1f489ee9217b88d09

[12] Wu, Z., Lamao, Q., Gu, M., Jin, X., Liu, Y., Tian, F., Yu, Y., Yuan, P., Gao, S., Fulford, T. S., Uldrich, A., Wong, C. C. L., & Wei, W. (2024). Unsynchronized butyrophilin molecules dictate cancer cell evasion of Vγ9Vδ2 T-cell killing. *Cellular & Molecular Immunology*. https://www.semanticscholar.org/paper/eb8ec4e2db0ba4ba29d9d043cae703008709e633

[13] Ding, X., Dang, X., & Lin, S. (2025). Identification of novel therapeutic targets for diabetic neuropathy through integrated proteomics and transcriptomics approaches. *World Journal of Diabetes*. https://www.semanticscholar.org/paper/2705f614dbd03ebb368cf91b56f703ef5555327e

[14] Chen, Y., Su, Y., Zhang, R., Wang, S., Zhang, J., Sun, X., Zhao, G., Ou, Q., Bao, H., & You, J. (2025). Deciphering tumor-intrinsic and immune characteristics in resectable non-small cell lung cancer treated with neoadjuvant pembrolizumab and chemotherapy. *Journal of Translational Medicine*. https://www.semanticscholar.org/paper/f5a50672704dd8b12271a1ea59469e22273da6b9

[15] Lehman, N., Bojarska-Junak, A., & Zarobkiewicz, M. (2025). Butyrophilin Downregulation in Chronic Lymphocytic Leukaemia: An Important Barrier to γδ T Cell-Mediated Cytotoxicity. *Biocell (Mendoza)*. https://www.semanticscholar.org/paper/f862a4ac1675c4072193cef28b28282cb8f88360

[16] Xu, W.-D., Wang, D.-C., Tang, Y.-Y., Huang, Q., Fu, L., Chen, Y.-Y., Yang, L.-Q., Feng, S.-Y., Su, L.-C., & Huang, A. (2025). Butyrophilin 3A1 Contributes to Inflammation and Induces a Lupus‐Like Disease by Inhibiting the IL‐38‐Ferroptosis Axis. *MedComm*. https://www.semanticscholar.org/paper/50a9e1e8401fee1cdd6ca41f81554497aae9b263

[17] Rigau, M., Ostrouska, S., Fulford, T. S., Johnson, D., Woods, K., Ruan, Z., McWilliam, H. E. G., Hudson, C., Tutuka, C., Wheatley, A., Kent, S., Villadangos, J., Pal, B., Kurts, C., Simmonds, J., Pelzing, M., Nash, A., Hammet, A., Verhagen, A., Vairo, G., Maraskovsky, E., Panousis, C., Gherardin, N., Cebon, J., Godfrey, D., Behren, A., & Uldrich, A. P. (2020). Butyrophilin 2A1 is essential for phosphoantigen reactivity by γδ T cells. *Science*. https://www.semanticscholar.org/paper/479abaa9a4016865f50805a5f72422e3d2dc9624

[18] Liu, Y., Lui, K. S., Ye, Z., Chen, L., & Cheung, A. K. L. (2024). Epstein–Barr Virus BRRF1 Induces Butyrophilin 2A1 in Nasopharyngeal Carcinoma NPC43 Cells via the IL-22/JAK3-STAT3 Pathway. *International Journal of Molecular Sciences*. https://www.semanticscholar.org/paper/2b6cb127b4522c651e2ba758d90d2b843e529d12

[19] Wang, Y., Ji, N., Zhang, Y., Chu, J., Pan, C., Zhang, P., Ma, W., Zhang, X., Xi, J., Chen, M., Zhang, Y., Zhang, L., & Sun, T. (2023). B7H3-targeting chimeric antigen receptor modification enhances antitumor effect of Vγ9Vδ2 T cells in glioblastoma. *Journal of Translational Medicine*. https://www.semanticscholar.org/paper/fa1039efbee57417ef579135cd40ba60b26ac566

[20] Liu, Y.-d., Lui, K., Ye, Z., Fung, T. Y., Chen, L., Sit, P. Y., Leung, C., Mak, N., Wong, K., Lung, H., Tanaka, Y., & Cheung, A. K. L. (2023). EBV latent membrane protein 1 augments γδ T cell cytotoxicity against nasopharyngeal carcinoma by induction of butyrophilin molecules. *Theranostics*. https://www.semanticscholar.org/paper/2d6f700612